WO2012062026A1 - 苦柯胺b盐及制备方法和用途 - Google Patents
苦柯胺b盐及制备方法和用途 Download PDFInfo
- Publication number
- WO2012062026A1 WO2012062026A1 PCT/CN2011/000479 CN2011000479W WO2012062026A1 WO 2012062026 A1 WO2012062026 A1 WO 2012062026A1 CN 2011000479 W CN2011000479 W CN 2011000479W WO 2012062026 A1 WO2012062026 A1 WO 2012062026A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- compound
- bitternamide
- reaction
- solution
- Prior art date
Links
- LHFBXINHIKXNEP-UHFFFAOYSA-N CN(CCCCN(CCCN)C(CCc(cc1OCc2ccccc2)ccc1OCc1ccccc1)=O)CCCNC(CCc(cc1)cc(OCc2ccccc2)c1OCc1ccccc1)=O Chemical compound CN(CCCCN(CCCN)C(CCc(cc1OCc2ccccc2)ccc1OCc1ccccc1)=O)CCCNC(CCc(cc1)cc(OCc2ccccc2)c1OCc1ccccc1)=O LHFBXINHIKXNEP-UHFFFAOYSA-N 0.000 description 1
- IWRAOCFRRTWUDF-UHFFFAOYSA-N NCCCN(CCCCNCCCNC(CCc(cc1)cc(O)c1O)=O)C(CCc(cc1O)ccc1O)=O Chemical compound NCCCN(CCCCNCCCNC(CCc(cc1)cc(O)c1O)=O)C(CCc(cc1O)ccc1O)=O IWRAOCFRRTWUDF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/25—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/122—Propionic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/124—Acids containing four carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/06—Oxalic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/14—Adipic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
- C07C57/44—Cinnamic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
- C07C59/50—Mandelic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
Definitions
- the invention belongs to the technical field of medicine, and particularly relates to a method for preparing a drug for preventing and treating sepsis, and a method for preparing a salt of chloramphenic acid B and a method for preparing the same. Background technique
- Sepsis is a systemic inflammatory response syndrome (SIRS) mediated by infectious agents. It is a common complication of patients with burns, trauma, tumors and infectious diseases. It has become a globally recognized intensive care unit. (ICU) The primary cause of death in patients.
- the existing clinical treatments for sepsis mainly include early use of antibiotics and correction of ischemic hypoxic damage. Conventional treatment of organ failure and shock has no specific treatment measures. Drug therapy is usually based on the empirical use of non-specific drugs such as glucocorticoids, insulin, and immunomodulators, but the efficacy has not been confirmed.
- anti-lipid A monoclonal antibody HA-1A (Centoxin) was used in the US Gulf War and post-burn sepsis treatment during the Gulf War. It has also been used clinically in some European countries and Japan, but Due to the adverse effects on septic shock, it failed to obtain FDA approval in 1992 and immediately disappeared from the European market.
- Recombinant human activated protein C (rhPC) is currently the only FDA-approved drug for the treatment of sepsis (trade name Xigris). Clinical trials have shown that rhAPC reduces the 28-day mortality rate in patients with sepsis and was approved by the FDA in November 2001.
- PAMPs pathogen-associated molecular patterns
- PRRs pattern recognition receptors
- Kukoamine B also known as scutellaria, is a naturally occurring alkaloid chemical structure isolated from the bone of Chinese medicine.
- the chemical structure is as follows:
- bitter bromide B in the different origins and harvesting seasons is quite different. Therefore, the direct extraction, isolation and purification of bitteramine B from plants can be used to prepare drugs for the prevention and treatment of sepsis. Stable, high production costs, high energy consumption and other shortcomings. Chemical synthesis provides a new method for the preparation of bitternamide B, and retrospective studies and patents have been traced, and no full chemical synthesis studies of bitternamide B have been observed.
- bitteramine B Compared to the natural product, bitteramine B, the bitteramine B salt exists as a new salt with a new chemical structure.
- the bitteramine B salt and its total chemical synthesis method no patents or literature reports have been reported so far, and no treatment for sepsis has been observed. In particular, no treatment for sepsis by simultaneously antagonizing multiple PAMPs (LPS and CpG DNA) has been observed. Report. Summary of the invention
- the present invention is directed to the above-mentioned deficiencies, and provides a bitteramine B salt and a preparation method thereof, and the present invention also provides a bitternamide B salt and a pharmaceutical composition comprising the bitteramine B salt in the preparation of a medicament for preventing and treating sepsis the use of.
- the use of bitternamide B salt and a pharmaceutical composition comprising bitternamide B salt for the treatment of sepsis has a novel mechanism of action, good efficacy, safety and reliability, and provides a new means for the treatment of sepsis.
- A is an inorganic acid of a anaerobic acid or an oxo acid or an organic acid of a carboxylic acid or a hydroxy acid or a sulfonic acid or an acidic amino acid.
- the bitternamide B salt forms an acid salt at a basic group portion of the compound structure, and includes an inorganic acid salt and an organic acid.
- the oxo acid is any one of hydrochloric acid and hydrobromic acid.
- the oxyacid is any one of sulfuric acid, phosphoric acid and nitric acid.
- the inorganic acid is any one of hydrochloric acid, hydrobromic acid, sulfuric acid and phosphoric acid, and the effect is good.
- the carboxylic acid is acetic acid, propionic acid, butyric acid, oxalic acid, malonic acid, succinic acid, adipic acid, benzoic acid, phenylpropionic acid, cinnamic acid, stearic acid, trifluoroacetic acid, maleic acid, and fumar. Any of acid, niacin and palmitic acid.
- the hydroxy acid is any one of malic acid, citric acid, lactic acid, hydroxybutyric acid, lactobionic acid, tartaric acid, mandelic acid, gluconic acid, glucuronic acid, and ascorbic acid.
- the sulfonic acid is any one of methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and camphorsulfonic acid.
- the acidic amino acid is any one of glutamic acid and aspartic acid.
- the organic acid is preferably any one of acetic acid, maleic acid, succinic acid, malic acid, lactic acid, tartaric acid, methanesulfonic acid, p-toluenesulfonic acid, glutamic acid and aspartic acid.
- the acid in the bitteramine salt is widely selected from a plurality of inorganic acids and/or organic acids, and is mainly prepared by selecting 2 to 3 representative acids from various types of acids which are allowed to be used in medicine.
- the common problem of ketamine salts is described, including hydrochloric acid and hydrobromic acid from the oxoacids in the inorganic acid, sulfuric acid and phosphoric acid in the oxyacid, and acetic acid, maleic acid and the carboxylic acid in the organic acid.
- malic acid is selected from malic acid, lactic acid and tartaric acid
- sulfonic acid is selected from methanesulfonic acid and p-toluenesulfonic acid
- acidic amino acid is selected from glutamic acid and aspartic acid.
- the medicament for preventing and treating sepsis prepared by using a bitteramine salt and a pharmaceutical composition comprising a bitteramine salt can be administered by the gastrointestinal tract, such as a powder, a tablet, a granule, a capsule.
- Dosing forms such as agents, solutions, emulsions, suspensions, etc.; or parenteral administration, such as administration by injection, intraluminal administration, mucosal administration, and the like.
- the dosage is 0.1 ⁇ 15mg per kilogram of body weight per day, and the dosage can be one or more times a day.
- bitternamide B salt obtained by synthesizing a series of chemical reactions using 3,4-dimethoxyphenylpropionic acid (or 3,4-dihydroxyphenylpropionic acid) and butanediamine as raw materials. as follows:
- the pharmaceutical composition of the bitternamide B salt comprises the above-mentioned bitternamide B salt as an active ingredient and a pharmaceutically acceptable carrier and/or diluent.
- bitternamide B salt in the preparation of a medicament for the prevention and treatment of sepsis.
- bitternamide B salt for the preparation of a medicament for the prevention and treatment of sepsis.
- the pharmaceutical composition of the bitternamide B salt of the present invention comprises the bitternamide B salt as an active ingredient and a pharmaceutically acceptable carrier and/or diluent.
- the bitternamide B salt of the present invention can be used for the preparation of a medicament for the prevention and treatment of sepsis.
- the bitteramine B salt can be combined with the active center of the LPS lipid A;
- bitteramine B salt can neutralize LPS in a dose-dependent manner in vitro
- the invention uses the bitternamide B salt and the pharmaceutical composition comprising the bitteramine B salt, and the novel mechanism of action for treating sepsis can simultaneously antagonize multiple PAMPs which mediate sepsis, unlike the existing glucocorticoids.
- insulin, anti-inflammatory mediators, anticoagulant drugs, anti-LPS peptides and lipidA monoclonal antibody can significantly inhibit the induced inflammatory response by simultaneously antagonizing multiple pathogenic molecules, providing treatment for sepsis A new means.
- the invention broadly selects a plurality of inorganic acids and/or organic acids for explaining the common problem of preparing bitteramine B salt, and those skilled in the chemical and pharmaceutical arts can understand that the same inorganic acid and/or organic acid can be the same.
- the bitternamide B salt is prepared by a method well known in the chemical art. It will also be understood by those skilled in the art that the bitteramine B can be obtained by extraction, isolation and purification from plants by conventional phytochemical methods. Therefore, it should be noted that the inorganic acid and/or organic acid listed in the present invention is replaced by other inorganic acids and/or organic acids, and the structural modification based on the design idea of the present invention is carried out on the naturally occurring or chemically synthesized bitteramine B. And the modifications are intended to be within the scope of the present invention and the scope of the invention is to be construed as being limited by the scope of the present invention.
- Figure 1 shows the binding reaction of bitternamide B salt to lipid A.
- A is an experimental result of bitternamide B malate, succinate, lactate, tartrate, methanesulfonate, hydrochloride and sulfate
- B is bitternamide B p-toluenesulfonate
- Figure 2 shows the in vitro neutralization of LPS by bitternamide B salt.
- A is an experimental result of bitternamide B malate, succinate, lactate, tartrate, methanesulfonate, hydrochloride and sulfate
- B is bitternamide B p-toluenesulfonate
- FIG. 3 shows that Kushen B salt inhibits the release of inflammatory mediators from RAW264.7 cells induced by LPS.
- A, B, C, D, E, F, G, H, I and J are respectively bitteramine B malate, succinate, lactate, tartrate, methanesulfonate, p-toluene
- Acid salts glutamates, acetates, hydrochlorides, and sulfates
- Figure 4 shows that the bitteramine B salt inhibits the release of inflammatory mediators from RAW264.7 cells induced by CpG DNA.
- A, B, C, D, E, F, G, H, I and J are respectively bitteramine B malate, succinate, lactate, tartrate, methanesulfonate, p-toluene
- Figure 5 shows the protective effects of bitternamide B hydrochloride, methanesulfonate, p-toluenesulfonate and besylate on sepsis model mice.
- LPS and CpG DNA are the key pathogenic factors leading to the pathogenesis of sepsis.
- the antagonistic effect of drugs on LPS and CpG DNA reflects its prevention and treatment of sepsis.
- reagents used herein are of analytical grade.
- HoN Replacement page (Article 26) (4) Weigh 30 g of compound c in a 250 ml round bottom flask, add 80 ml of THF and 26 ml of triethylamine, and add 21 ml of a mixture of Cbz-Cl and 50 ml of THF at room temperature with stirring. After that, the reaction was stirred at room temperature. After TLC monitoring, after completion of the reaction, the organic solvent was evaporated to dryness, ethyl acetate was extracted, and the mixture was extracted with ethyl acetate.
- Example 15 Determination of affinity of bitternamide B salt with lipid A
- the lipidA is coated on the non-derivatized sample cell.
- the hydrophobic side chain of the lipid A is combined with the sample pool, and the hydrophilic end is free on the outer side, as the hair The target of the binding effect.
- bitternamide B hydrochloride hydrobromide, sulfate, phosphate, acetate, maleate, succinate, malate, lactate, tartrate, methanesulfonic acid Salt, p-toluenesulfonate, glutamate and aspartate, respectively, in a solution of 20 ⁇ in pyrogen-free water;
- RAW264.7 cells were diluted to lxl0 6 /ml in DMEM medium and added to 96-well plates (200 ⁇ /well), incubate for 4 hours at 37 ° C, volume fraction of 5% C0 2 , after adherence, replace the cell supernatant with 200 ⁇ serum-free DMEM medium, then add LPS (final concentration 100 ng/ Ml), simultaneously add various bitteramine B salts (including bitteramine, malate, lactic acid, lactate, tartrate, methanesulfonate) at a final concentration of 0, 50, 100, 200 ⁇ M , p-toluenesulfonate, glutamate, acetate, hydrochloride and sulfate), blank control group (Medium) without LPS, continue to incubate for 4 hours, take the supernatant, according to the ELISA kit instructions The concentration of TNF-ct.
- LPS final concentration 100 ng/ Ml
- various bitteramine B salts including bitteramine, mal
- RAW264.7 cells were diluted to lxl6 6 /ml in DMEM medium, added to a 96-well plate (200 ⁇ /well), and incubated for 4 hours at 37 ° C with a volume fraction of 5% C0 2 . After adherence, the cell supernatant was changed to 200 ⁇ l serum-free DMEM medium, then CpG DNA (final concentration 10 g/ml) was added, and various bitteramines were added at a final concentration of 0, 50, 100, 200 ⁇ M.
- B salt including bitteramine, malate, succinate, lactate, tartrate, methanesulfonate, p-toluenesulfonate, glutamate, acetate, hydrochloride and sulfate
- blank control group Medium
- mice 19-21 g, male and female, a total of 120, were randomly divided into 6 groups, 20 in each group, respectively, control group, antibiotic administration group, antibiotic combined with bitteramine B salt
- the mice were anesthetized with an anesthesia machine, the isoflurane output concentration was 5%, the mixed gas pressure was I MPa, and the anesthesia time was about 5 minutes.
- the cecal ligation and puncture (CLP) was used to make the model.
- the mouse was placed in the supine position, and the lower abdomen was passed through the skin.
- iodophor disinfection use the ophthalmology scissors to cut the skin, muscle layer and peritoneum (incision length about 0.8 cm) downwards 0.3 cm below the midpoint of the abdominal white line.
- the muscle layer was clamped with an ophthalmology, and the abdominal cavity was examined with an ophthalmologist under direct vision.
- the end of the cecum was removed and placed outside the abdominal wall, and then ligated with a 4 suture at a distance of 0.5 cm from the end of the cecum.
- the control group was injected with 0.2 ml of normal saline in the tail vein; the antibiotic (sulphate) in the drug-administered group was administered at a dose of 80 mg/kg, and injected intravenously 4 hours after the mouse was modeled; Kushen B hydrochloride, A
- the dosage of sulfonate, p-toluenesulfonate and besylate was 2.5 mg/kg, respectively, 0, 4, 12, 20, 28, 36, 44, 52 after surgery in mice. , 60 and 68 hours of tail vein injection.
- the general state and mortality of the animals were observed within 7 days, and the difference in survival between the control group and the drug-administered group was compared.
- the 7-day mortality rate of the CLP control group was 95%, and the survival rate of the sulphatecil (80 mg/kg) mice was 15%.
- the bitteramine B and the p-toluenesulfonate can increase the survival rate to 20%, the bitteramine B-besylate can increase the survival rate to 30%, and the bitteramine B mesylate can survive. The rate was increased to 50%.
- the results showed that bitteramine B hydrochloride, methanesulfonate, p-toluenesulfonate and besylate have protective effects on sepsis model mice, among which, bitteramine B Methanesulfonate works best. The result is shown in Figure 5.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013538030A JP5809286B2 (ja) | 2010-11-10 | 2011-03-21 | クコアミンbの塩の製造方法 |
US13/884,558 US9365504B2 (en) | 2010-11-10 | 2011-03-21 | Salts of kukoamine B, preparation method and use thereof |
EP11840357.5A EP2639215B1 (en) | 2010-11-10 | 2011-03-21 | Preparation method for salts of kukoamine b |
CA2817263A CA2817263C (en) | 2010-11-10 | 2011-03-21 | Salts of kukoamine b, preparation method and use thereof |
IL225972A IL225972A (en) | 2010-11-10 | 2013-04-25 | Cocoamine b salts, a method of preparation and use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010539028.4A CN102464591B (zh) | 2010-11-10 | 2010-11-10 | 苦柯胺b盐及制备方法和用途 |
CN201010539028.4 | 2010-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012062026A1 true WO2012062026A1 (zh) | 2012-05-18 |
Family
ID=46050336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2011/000479 WO2012062026A1 (zh) | 2010-11-10 | 2011-03-21 | 苦柯胺b盐及制备方法和用途 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9365504B2 (zh) |
EP (1) | EP2639215B1 (zh) |
JP (2) | JP5809286B2 (zh) |
CN (1) | CN102464591B (zh) |
CA (1) | CA2817263C (zh) |
IL (1) | IL225972A (zh) |
WO (1) | WO2012062026A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150065752A1 (en) * | 2013-09-03 | 2015-03-05 | City University Of Hong Kong | Process for isolating kukoamine |
CN104725278A (zh) * | 2015-01-23 | 2015-06-24 | 天津红日药业股份有限公司 | 一种苦柯胺b中间体的制备方法 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101829075B (zh) | 2010-04-27 | 2011-07-20 | 中国人民解放军第三军医大学第一附属医院 | 苦柯胺a和苦柯胺b的用途 |
CN102641240B (zh) * | 2012-05-22 | 2014-07-16 | 天津红日药业股份有限公司 | 一种苦柯胺b盐注射剂及其制备方法 |
CN103769060B (zh) * | 2014-01-23 | 2015-10-21 | 重庆安体新生物技术有限公司 | 用于清除细菌内毒素、dna和肽聚糖的吸附剂和制备方法及用途 |
CN103819356A (zh) * | 2014-02-12 | 2014-05-28 | 天津红日药业股份有限公司 | 一种苦柯胺b的类似物或其药用盐的制备方法及用途 |
CN105330563B (zh) * | 2015-10-12 | 2018-12-07 | 天津红日药业股份有限公司 | 用于苦柯胺b质量控制中的参比化合物 |
CN105348137B (zh) * | 2015-10-29 | 2018-06-12 | 重庆安体新生物技术有限公司 | 多胺衍生物药用盐及制备方法和用途 |
CN110491455B (zh) * | 2019-07-22 | 2023-01-24 | 广州中医药大学(广州中医药研究院) | 地骨皮乙素在制备抗肿瘤药物中的应用 |
CN110963940A (zh) * | 2019-12-24 | 2020-04-07 | 广州中医药大学(广州中医药研究院) | 一种地骨皮乙素衍生物化合物及其制备方法和应用 |
WO2024046175A1 (zh) * | 2022-08-29 | 2024-03-07 | 武汉武药科技有限公司 | 一种多胺衍生物药用盐及其晶型和制备方法 |
CN115557857B (zh) * | 2022-10-09 | 2024-05-24 | 天津红日药业股份有限公司 | 一种苦柯胺b中间体及其制备方法与甲磺酸苦柯胺b的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101829075A (zh) * | 2010-04-27 | 2010-09-15 | 中国人民解放军第三军医大学第一附属医院 | 苦柯胺a和苦柯胺b的用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100517738B1 (ko) * | 2003-06-03 | 2005-09-30 | 김영숙 | 구기자를 함유한 누룽지 스넥 및 그 제조 방법 |
-
2010
- 2010-11-10 CN CN201010539028.4A patent/CN102464591B/zh active Active
-
2011
- 2011-03-21 JP JP2013538030A patent/JP5809286B2/ja active Active
- 2011-03-21 CA CA2817263A patent/CA2817263C/en active Active
- 2011-03-21 WO PCT/CN2011/000479 patent/WO2012062026A1/zh active Application Filing
- 2011-03-21 EP EP11840357.5A patent/EP2639215B1/en active Active
- 2011-03-21 US US13/884,558 patent/US9365504B2/en active Active
-
2013
- 2013-04-25 IL IL225972A patent/IL225972A/en active IP Right Grant
-
2015
- 2015-09-10 JP JP2015178139A patent/JP2016029053A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101829075A (zh) * | 2010-04-27 | 2010-09-15 | 中国人民解放军第三军医大学第一附属医院 | 苦柯胺a和苦柯胺b的用途 |
Non-Patent Citations (4)
Title |
---|
FUNAYAMA S. ET AL.: "Kukoamine B, a spermine alkaloid from Lycium chinense", PHYTOCHEMISTRY, vol. 38, no. 6, 1995, pages 1529 - 1531, XP055086442 * |
KARIGIANNIS G. ET AL.: "Simple fragment syntheses of all four isomers of the spermine alkaloid kukoamine.", TETRAHEDRON LETTERS, vol. 39, no. 28, 1998, pages 5117 - 5120, XP004501731 * |
S. FUNAYAMA; G. ZHANG; S. NOZOE, PHYTOCHEMISTRY, vol. 38, 1995, pages 1529 - 1531 |
See also references of EP2639215A4 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150065752A1 (en) * | 2013-09-03 | 2015-03-05 | City University Of Hong Kong | Process for isolating kukoamine |
CN104418761A (zh) * | 2013-09-03 | 2015-03-18 | 香港城市大学 | 苦可胺的分离方法 |
US9012687B2 (en) * | 2013-09-03 | 2015-04-21 | City University Of Hong Kong | Process for isolating kukoamine |
CN104725278A (zh) * | 2015-01-23 | 2015-06-24 | 天津红日药业股份有限公司 | 一种苦柯胺b中间体的制备方法 |
CN104725278B (zh) * | 2015-01-23 | 2017-01-25 | 天津红日药业股份有限公司 | 一种苦柯胺b中间体的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2014501708A (ja) | 2014-01-23 |
CN102464591B (zh) | 2016-08-24 |
CN102464591A (zh) | 2012-05-23 |
EP2639215B1 (en) | 2017-10-11 |
EP2639215A1 (en) | 2013-09-18 |
CA2817263C (en) | 2017-01-24 |
IL225972A0 (en) | 2013-06-27 |
JP5809286B2 (ja) | 2015-11-10 |
US20130289112A1 (en) | 2013-10-31 |
CA2817263A1 (en) | 2012-05-18 |
IL225972A (en) | 2016-09-29 |
EP2639215A4 (en) | 2014-04-23 |
JP2016029053A (ja) | 2016-03-03 |
US9365504B2 (en) | 2016-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012062026A1 (zh) | 苦柯胺b盐及制备方法和用途 | |
CN110357800B (zh) | 脯氨酸衍生物及其在制备治疗心脑血管疾病药物中的应用 | |
WO2019196955A1 (zh) | R 10与r 11连接的亲水性小檗碱型衍生物及其制备药物的应用 | |
WO2022078352A1 (en) | Crystal forms of glp-1r agonists and uses thereof | |
NO157452B (no) | Analogifremgangsmaate for fremstilling av et terapeutisk aktivt bispidinderivat. | |
WO2023087611A1 (zh) | 一类依巴斯汀的盐及其制备方法和应用 | |
CN110256522B (zh) | 雷公藤红素肉桂酸酯类衍生物及其制备方法与用途 | |
WO2022028367A1 (zh) | 化合物的固体形式 | |
EP2970105B1 (en) | Non-peptide bdnf neurotrophin mimetics | |
CN107033154A (zh) | 阿片受体拮抗剂缀合物及其应用 | |
JP2020528882A (ja) | フェノラミンb型結晶、その製造方法並びにその組成物及び用途 | |
AU2014227623A1 (en) | Non-peptide BDNF Neurotrophin mimetics | |
JP2012505166A (ja) | 1‐ブチル‐2‐ヒドロキシアラルキルピペラジン誘導体およびその抗鬱剤としての使用 | |
CN106866652A (zh) | 具有胰岛素增敏活性的小檗碱12‑位衍生物及其制备方法 | |
SU1017170A3 (ru) | Способ получени производных 3-амино-1-бензоксепина или их стереоизомеров, или их солей | |
CN100999519B (zh) | (-)多沙唑嗪甲磺酸盐、其制备方法及用途 | |
CN103127520B (zh) | 聚乙二醇与坦索罗辛的结合物及其药物组合物 | |
JP2021512851A (ja) | ピラノース置換複素環式化合物の塩、その調製方法および用途 | |
CN102260249B (zh) | (-)多沙唑嗪甲磺酸盐ⅱ型结晶、其制备方法及用途 | |
CN115850137B (zh) | 一种截短侧耳素衍生化合物及其制备方法与应用 | |
CN113845533B (zh) | 双-4,5-二芳基咪唑环卡宾金配合物及其制备方法和应用 | |
CN110139855B (zh) | 新型的氘代脲类化合物 | |
CN111606828B (zh) | (E)-α,β-不饱和酰胺化合物的晶型及其制备方法和用途 | |
WO2023236927A1 (zh) | 4-羰基氨基异吲哚啉-1,3-二酮类化合物及其制备方法、药物组合及用途 | |
WO2007136302A2 (fr) | Substances actives, composition pharmaceutique et procédé de fabrication et d'utilisations correspondants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11840357 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 225972 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2817263 Country of ref document: CA Ref document number: 2013538030 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2011840357 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011840357 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13884558 Country of ref document: US |